Skip to content

Study · Randomized controlled trial · 2020

4 results

Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.

Tougaard RS, Jorsal A, Tarnow L, Hansson NH, Kistorp C, Schou M, Nielsen R, Flyvbjerg A, Videbaek L, Mølgaard H, Nielsen JC, Gustafsson I, Wiggers H

Scandinavian cardiovascular journal : SCJ15 Apr 2020Cited by 13 (Europe PMC)

PMID32292074 (opens in a new tab)DOI10.1080/14017431.2020.1751873 (opens in a new tab)PepBankPUB-32292074
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure and sinus rhythm, liraglutide increased heart rate versus placebo by about 8 to 9 bpm across three measurement methods.

    In plain wordsIn people with chronic heart failure and a normal rhythm, liraglutide raised heart rate by about 8 to 9 beats per minute compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate change in patients with sinus rhythm
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Measurements

    Heart rate increase
    8 bpm
    pulse measurements
    Heart rate increase
    9 bpm
    ECG measurements
    Heart rate increase
    9 bpm
    device readouts

    Source sentences

    Summary
    In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005).
    1 context sentence
    Summary · context
    CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure treated with liraglutide, the heart rate increase correlated with liraglutide dose.

    In plain wordsIn people with chronic heart failure, a higher liraglutide dose was linked to a larger rise in heart rate.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate increase and liraglutide dose
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Increases in HR correlated with liraglutide dose (p=.01).
    1 context sentence
    Summary · context
    CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure but without sinus rhythm, heart rate remained unchanged with liraglutide.

    In plain wordsIn people with chronic heart failure and no normal rhythm, liraglutide did not change heart rate.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeart rate in patients without sinus rhythm
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    HR remained unchanged in patients without SR.
    1 context sentence
    Summary · context
    CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with chronic heart failure treated with liraglutide, serious cardiac adverse events were not associated with heart rate changes.

    In plain wordsIn people with chronic heart failure on liraglutide, serious heart problems were not linked to the rise in heart rate.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious cardiac adverse events and heart rate change
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    1.8 mg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Serious cardiac adverse events were not associated with HR changes.
    1 context sentence
    Summary · context
    CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.